Augmented Berlin-Frankfurt-Munster (BFM) Therapy for Adolescent/Young Adults With Acute Lymphoblastic Leukemia or Acute Lymphoblastic Lymphoma
Active, not recruiting
M.D. Anderson Cancer Center
A. Primary objective:
1 To assess the feasibility and the effectiveness of pediatric type therapy (augmented BFM)
in patients age 12 through 40 with untreated precursor-B or T acute lymphoblastic leukemia
(ALL) or lymphoblastic lymphoma (LL).
B. Secondary objective:
1. To evaluate the prognostic significance of minimal residual disease in bone marrow
samples at the end of induction and at the end of consolidation in this group of
2. To prospectively evaluate gene hypermethylation status in this group of patients.
3. To prospectively analyze asparaginase activity and anti-asparaginase antibody formation
in this population of patients.
First-line Dasatinib Plus Conventional Chemotherapy in Adults With Newly Diagnosed Ph-Positive ALL
The Catholic University of Korea
The main aim of the present study is to evaluate the clinical efficacy of first-line
dasatinib plus conventional chemotherapy for newly diagnosed Ph-positive acute lymphoblastic
leukemia. In this study, the investigators will analyze the clinical outcomes for entire
patient population as well as those for transplants, respectively. In addition, the results
of this study will be compared to those of the investigators current study (imatinib plus
conventional chemotherapy). The safety of this treatment will also be studied.
A Study to Assess AC220 Given in Combination With Induction and Consolidation Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML)
Ambit Biosciences Corporation
The purpose of this study is to define the maximum tolerated dose (MTD) of AC220 when
combined with induction and consolidation therapy and as maintenance therapy following
induction and consolidation.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.